Evidence map›Paper›PMID 26477312›Full record

ArticleOncogene2016

NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.

K R Manda, P Tripathi, A C Hsi, J Ning, M B Ruzinova, H Liapis, M Bailey, H Zhang, C A Maher, P A Humphrey and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. LowJournal of Cancer · 2023
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. PGRMC1 Inhibits Progesterone-Evoked Proliferation and CaInternational journal of molecular sciences · 2020
    Article
  16. Review
  17. Article
  18. Down-Regulation of Nfatc1 Suppresses Proliferation, Migration, Invasion, and Warburg Effect in Prostate Cancer Cells.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

K R MandaDepartment of Medicine, Washington University, School of Medicine, St Louis, MO, USA.
P TripathiDepartment of Pathology and Immunology, Washington University, St Louis, MO, USA.
A C HsiThe Genome Institute, Washington University, St Louis, MO, USA.
J NingDepartment of Medicine, Washington University, School of Medicine, St Louis, MO, USA.
M B RuzinovaDepartment of Pathology and Immunology, Washington University, St Louis, MO, USA.
H LiapisDepartment of Pathology and Immunology, Washington University, St Louis, MO, USA.
M BaileyThe Genome Institute, Washington University, St Louis, MO, USA.
H ZhangDepartment of Cell and Developmental Biology, University of Massachusetts Medical School, Worcester, MA, USA.
C A MaherDepartment of Medicine, Washington University, School of Medicine, St Louis, MO, USA.
P A HumphreyDepartment of Pathology, Yale University, New Haven, CT, USA.
G L AndrioleSiteman Cancer Center, Washington University, St Louis, MO, USA.
L DingDepartment of Medicine, Washington University, School of Medicine, St Louis, MO, USA.
Z YouDepartment of Structural and Cellular Biology, Tulane University, New Orleans, LA, USA.
F ChenDepartment of Medicine, Washington University, School of Medicine, St Louis, MO, USA.
Washington University in St. Louis · USTulane University · USUniversity of Massachusetts Chan Medical School · USYale University · US

Funding

A Turnkey System for High-throughput Variant Discovery and InterpretationU01HG006517 · NHGRI · WASHINGTON UNIVERSITY · PI DING, LI · 2012 to 2015
$3.0M
NFAT SIGNALING IN GLOMERULOSCLEROSISR01DK087960 · NIDDK · WASHINGTON UNIVERSITY · PI CHEN, FENG · 2010 to 2014
$1.6M
The role of IL-17 in prostate cancerR01CA174714 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI YOU, ZONGBING · 2013 to 2017
$1.6M
CANCER SUSCEPTIBILITY VARIANT DISCOVERY IN HIGH THROUGHPUT SEQUENCING DATAR01CA180006 · NCI · WASHINGTON UNIVERSITY · PI DING, LI · 2013 to 2016
$1.1M
VIRUS DISCOVERY AND CHARACTERIZATION IN LARGE-SCALE CANCER SEQUENCING DATAR01CA178383 · NCI · WASHINGTON UNIVERSITY · PI DING, LI · 2014 to 2016
$772k
NCI NIH HHS R01 CA174714NCI NIH HHS R01 CA178383NCI NIH HHS R01 CA180006NHGRI NIH HHS U01 HG006517NIDDK NIH HHS R01 DK087960
6 · The paper itself

Abstract

Despite recent insights into prostate cancer (PCa)-associated genetic changes, full understanding of prostate tumorigenesis remains elusive owing to complexity of interactions among various cell types and soluble factors present in prostate tissue. We found the upregulation of nuclear factor of activated T cells c1 (NFATc1) in human PCa and cultured PCa cells, but not in normal prostates and non-tumorigenic prostate cells. To understand the role of NFATc1 in prostate tumorigenesis in situ, we temporally and spatially controlled the activation of NFATc1 in mouse prostate and showed that such activation resulted in prostatic adenocarcinoma with features similar to those seen in human PCa. Our results indicate that the activation of a single transcription factor, NFATc1 in prostatic luminal epithelium to PCa can affect expression of diverse factors in both cells harboring the genetic changes and in neighboring cells through microenvironmental alterations. In addition to the activation of oncogenes c-MYC and STAT3 in tumor cells, a number of cytokines and growth factors, such as IL1β, IL6 and SPP1 (osteopontin, a key biomarker for PCa), were upregulated in NFATc1-induced PCa, establishing a tumorigenic microenvironment involving both NFATc1 positive and negative cells for prostate tumorigenesis. To further characterize interactions between genes involved in prostate tumorigenesis, we generated mice with both NFATc1 activation and Pten inactivation in prostate. We showed that NFATc1 activation led to acceleration of Pten null-driven prostate tumorigenesis by overcoming the PTEN loss-induced cellular senescence through inhibition of p21 activation. This study provides direct in vivo evidence of an oncogenic role of NFATc1 in prostate tumorigenesis and reveals multiple functions of NFATc1 in activating oncogenes, in inducing proinflammatory cytokines, in oncogene addiction, and in overcoming cellular senescence, which suggests calcineurin-NFAT signaling as a potential target in preventing PCa.

Indexed as

AnimalsBlotting, WesternCell LineCell Line, TumorCell ProliferationCell Transformation, NeoplasticCellular SenescenceCytokinesGene Expression Regulation, NeoplasticHumansImmunohistochemistryMaleMice, KnockoutMice, NudeMice, TransgenicNFATC Transcription FactorsCytokinesNFATC Transcription FactorsPTEN Phosphohydrolase

Identifiers

PMID26477312
PMCPMC5012433
OpenAlexW1809878175

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.